参考文献 References
[1] 国务院办公厅. 关于加快医学教育创新发展的指导意见(国办发〔2020〕34号)[EB/OL]. (2020-09-17)[2025-11-10]. 可获得:
https://www.gov.cn/zhengce/content/2020-09/23/content_5546373.htm.
[2] 中共中央, 国务院. 教育强国建设规划纲要(2024—2035年)[EB/OL]. (2025-05-20)[2025-11-10]. 可获得:
https://www.gov.cn/zhengce/202501/content_6999914.htm.
[3] 教育部. 国家教育数字化战略行动2025年部署会召开[EB/OL]. (2025-03-28)[2025-11-10]. 可获得:
http://www.moe.gov.cn/jyb_xwfb/gzdt_gzdt/moe_1485/202503/t20250328_1185222.html.
[4] 郑永和, 王佳宁, 陶丹. 科教协同促进科学教育高质量发展: 内涵、意义、现状与路径[J]. 电化教育研究, 2024, 45(10): 5-11.
[5] FERREIRA FJN, CARNEIRO AS. AI-driven drug discovery: A comprehensive review[J]. ACS Omega, 2025, 10(23): 23889-23903.
[6] TONG X, QU N, KONG X, et al. Deep representation learning of chemical-induced transcriptional profile for phenotype-based drug discovery[J]. Nat Commun, 2024, 15(1): 5378.
[7] REN F, ALIPER A, CHEN J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models[J]. Nat Biotechnol, 2025, 43(1): 63-75.
[8] DESAI D, KANTLIWALA SV, VYBHAVI J, et al. Review of AlphaFold 3: Transformative advances in drug design and therapeutics[J]. Cureus, 2024, 16(7): e63646.
[9] ABRAMSON J, ADLER J, DUNGER J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3[J]. Nature, 2024, 630(8016): 493-500.
[10] 澳门理工大学应用科学学院. 人工智能药物发现博士学位课程[EB/OL]. [2025-11-10]. 可获得:
https://www.mpu.edu.mo/esca/zh/phd_aidd.php.
[11] 杨龙华, 单丽红, 张恩, 等. 人工智能在计算机辅助药物设计模块教学中的应用与思考[J]. 药学教育, 2025, 41(5): 27-32.
[12] 杜佳恬, 李琰, 何勤, 等. 在协调发展理念指导下的药学课程结构改革思考与初步实践[J]. 四川大学学报(医学版), 2022, 53(2): 281-284.
[13] ANGELO JS, GUEDES IA, BARBOSA HJC, et al. Multi- and many-objective optimization: Present and future in de novo drug design[J]. Front Chem, 2023, 11: 1288626.
[14] ZENG X, WANG F, LUO Y, et al. Deep generative molecular design reshapes drug discovery[J]. Cell Rep Med, 2022, 3(12): 100794.
[15] ABEER ANMN, URBAN NM, WEIL MR, et al. Multi-objective latent space optimization of generative molecular design models[J]. Patterns (N Y), 2024, 5(10): 101042.
[16] YANG Y, CHEN G, LI J, et al. Enabling target-aware molecule generation to follow multi objectives with Pareto MCTS[J]. Commun Biol, 2024, 7(1): 1074.
[17] KADAN A, RYCZKO K, LLOYD E, et al. Guided multi-objective generative AI to enhance structure-based drug design[J]. Chem Sci, 2025, 16(29): 13196-13210.
[18] LOEFFLER HH, HE J, TIBO A, et al. Reinvent 4: Modern AI-driven generative molecule design[J]. J Cheminform, 2024, 16(1): 20.
[19] VARADI M, BERTONI D, MAGANA P, et al. AlphaFold Protein Structure Database in 2024: Providing structure coverage for over 214 million protein sequences[J]. Nucleic Acids Res, 2024, 52(D1): D368-D375.
[20] BLANCO-GONZÁLEZ A, CABEZÓN A, SECO-GONZÁLEZ A, et al. The role of AI in drug discovery: Challenges, opportunities, and strategies[J]. Pharmaceu-ticals (Basel), 2023, 16(6): 891.
[21] MOFFAT JG, VINCENT F, LEE JA, et al. Opportunities and challenges in phenotypic drug discovery: An industry perspective[J]. Nat Rev Drug Discov, 2017, 16(8): 531-543.
[22] LIU G, CATACUTAN DB, RATHOD K, et al. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii[J]. Nat Chem Biol, 2023, 19(11): 1342-1350.
[23] STOKES JM, YANG K, SWANSON K, et al. A deep learning approach to antibiotic discovery[J]. Cell, 2020, 180(4): 688-702.e13.
[24] LIU X, LU Y, CHEN Q, et al. Deep learning-based discovery of tetrahydrocarbazoles as broad-spectrum antitumor agents and click-activated strategy for targeted cancer therapy[J]. Acta Pharm Sin B, 2025.
[25] BUTTENSCHOEN M, MORRIS GM, DEANE CM. PoseBusters: AI-based docking methods fail to generate physically valid poses or generalise to novel sequences[J]. Chem Sci, 2024, 15(9): 3130-3139.
[26] VAN TILBORG D, ALENICHEVA A, GRISONI F. Exposing the limitations of molecular machine learning with activity cliffs[J]. J Chem Inf Model, 2022, 62(23): 5938-5951.
[27] WOGNUM C, ASH JR, ALDEGHI M, et al. A call for an industry-led initiative to critically assess machine learning for real-world drug discovery[J]. Nat Mach Intell, 2024, 6(10): 1120-1121.
[28] WORLD HEALTH ORGANIZATION. WHO releases AI ethics and governance guidance for large multi-modal models[EB/OL]. (2024-01-18)[2025-11-10]. Available from: https://www.who.int/news/item/18-01-2024-who-releases-ai-ethics-and-governance-guidance-for-large-multi-modal-models.
[29] VARADI M, ANYANGO S, DESHPANDE M, et al. AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models[J]. Nucleic Acids Res, 2022, 50(D1): D439-D444.
[30] CHENG J, NOVATI G, PAN J, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense[J]. Science, 2023, 381(6664): eadg7492.
[31] ALM RA, LAHIRI SD. Narrow-spectrum antibacterial agents—benefits and challenges[J]. Antibiotics (Basel), 2020, 9(7): 418.
[32] KHURANA MP, CURRAN-SEBASTIAN J, BHATT S, et al. Modelling the implementation of narrow versus broader spectrum antibiotics in the empiric treatment of E. coli bacteraemia[J]. Sci Rep, 2024, 14(1): 16986.
[33] STRUBELL E, GANESH A, MCCALLUM A. Energy and policy considerations for deep learning in NLP[C]//Proceedings of the 57th Annual Meeting of the Association for Computational Linguistics. Florence, Italy: Association for Computational Linguistics, 2019: 3645-3650.